Chapter

Therapeutic HPV vaccines

Sjoerd H van der Burg

in Vaccines for the Prevention of Cervical Cancer

Published on behalf of Oxford University Press

ISBN: 9780199543458
Published online May 2011 | e-ISBN: 9780199607181 | DOI: http://dx.doi.org/10.1093/med/9780199543458.003.0013

Series: Oxford Oncology Library

Therapeutic HPV vaccines

Show Summary Details

Preview

• Therapeutic vaccines aim to induce or boost HPV T-cell adaptive immunity when it is insufficient or has failed to develop naturally. • The high-risk HPV type oncogenes E6 and E7 are obligate for driving the malignant process in cervical neoplasia and are the preferred targets. • Vaccines based on viral protein or peptides together with adjuvants which act to stimulate the desired balance of T-cell response, or naked DNA, viral, or bacterial vectors encoding the viral targets have been tested in preclinical animal models. • Early phase clinical trials of therapeutic vaccines in cervical cancer patients have shown evidence of immunogenicity and safety, but clinical efficacy has not been established. In part, this is because of the complexity of immunological escape mechanisms which the tumour has utilized during its evolution. • Trials aimed at treating HPV-persistent infection in recalcitrant VIN 3 are a useful proving ground for testing combined treatment modalities that include vaccination to focus the cellular immunity away from negative influences of T regulatory cells.

Chapter.  4174 words.  Illustrated.

Subjects: Medical Oncology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.